Back to search

University of British Columbia

Rh2 and its aglycone aPPD in combination therapy with docetaxel - pre-clinical evaluation in a PC-3 human prostate

Abstract

dc:description

PURPOSE: The purpose of this thesis is to establish the therapeutic potential of ginsenoside Rh2, a 20(S)-protopanaxadiol type and its aglycone aPPD, two gastrointestinal metabolites of Panax Ginseng C.A. Meyer, for use in advanced prostate cancer. This thesis assesses (i) the pharmacokinetics, biodistribution and efficacy of Rh2 and aPPD as single agents, and (ii) the combination of Rh2 or aPPD with docetaxel with the goal of optimizing their therapeutic potential. METHODS: The solubility and stability of Rh2 and aPPD in ethanol was determined and an oral dosage formulation was prepared. Rh2 and aPPD levels in blood and tissues following administration to nulnu nude mice were determined by LC/MS. Their efficacy as single agents and in combination with docetaxel was determined in a PC-3 human prostate cancer xenograft model. Serum levels of AST, ALT, and creatinine were measured for toxicity. Tumor analysis for apoptotic indices and Ki-67 was performed. In vitro, PC-3, LNCaP, DU145, and C4-2 prostate cancer cells were treated with a combination of Rh2 or aPPD with docetaxel, according to the constant ratio combination design. RESULTS: The solubility of Rh2 and aPPD in ethanol was 130 and 68.4 mg/ml respectively. In vitro, Rh2+docetaxel and aPPD+docetaxel both showed synergy (CI < 1) against PC-3 and DU145 cells. In vivo, Rh2 and aPPD exhibited a Cmax of 19.0 ± 2.0 and 3.9 ± 1.4 jtg/ml, respectively, while no toxicity was observed. They engendered a significant delay in PC-3 tumor growth, an increase in apoptotic index, and a decrease in Ki-67 levels. Docetaxel alone inhibited tumor growth by 84% but could not induce tumor regression while Rh2+docetaxel and aPPD+docetaxel caused established PC-3 tumors to regress from their initial size by 15 and 27% respectively. CONCLUSIONS: We have shown that Rh2 and aPPD are stable compounds that can be formulated for oral gavage. Pharmacokinetic studies demonstrate their ability to be absorbed following oral administration. Rh2 and aPPD can be combined with docetaxel to yield synergistic inhibition of cancer cell growth in vitro. Their in vivo combinations with docetaxel in a PC-3 xenograft model induce significant tumor regression compared to docetaxel dosed alone.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Pathology
Grantor dc:publisher
University of British Columbia
Year dc:date
2008

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Musende, Alain G.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/5740

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Musende, Alain G.. Rh2 and its aglycone aPPD in combination therapy with docetaxel - pre-clinical evaluation in a PC-3 human prostate. doctoral thesis, University of British Columbia, 2008. http://hdl.handle.net/2429/5740